By Matt Grossman


Pfizer Inc. on Tuesday raised its full-year revenue and earnings guidance, citing a higher estimate of sales of its Covid-19 vaccine.

Pfizer now expects full-year revenue of $70.5 billion to $72.5 billion, compared with previous guidance for revenue of $59.4 billion to $61.4 billion.

The company forecast a full-year adjusted profit of $3.55 a share to $3.65 a share. It had previously said it expected an adjusted profit of $3.10 a share to $3.20 a share.

Pfizer expects its Covid-19 vaccine developed with BioNTech SE to generate revenue of about $26 billion in the year. It had previously guided for revenue of about $15 billion from the shot.


Write to Matt Grossman at


(END) Dow Jones Newswires

May 04, 2021 07:21 ET (11:21 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.